Medicines & Healthcare products Regulatory Agency

MHRA

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Mrs E Lawrie
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE
HAEMATOLOGY TRIALS GROUP
90 TOTTENHAM COURT ROAD
LONDON
W1T 4TJ
UNITED KINGDOM

31/08/2018

Dear Mrs E Lawrie

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	20363/0273/001-0021
Eudract Number:	2009-012717-22
Product:	rituximab
Protocol number:	UCL/08/0167
Substantial Amendment Code Number:	Code Number: Substantial Amendment (Protocol v12) MHRA
Version:	
Date: 2018/07/27	

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 27/07/2018.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

Clinical Trials Unit
MHRA